Scientists uncover new gut microbes in Africa and say their findings could help make medicines more effective.

Ethiopia's Tigray region was once considered a model in the country's fight against HIV. Years of awareness-raising efforts ...

The Trump administration is discussing cuts to the CDC’s domestic HIV program, including funding for prevention, according to two former HHS officials who were granted anonymity to discuss their ...

THURSDAY, March 20, 2025 (HealthDay News) -- The Trump administration is weighing elimination of the U.S. Centers for Disease Control and Prevention’s (CDC) Division on HIV Prevention ...

Photo of the U.S. Food and Drug Administration logo on a website The Trump administration may eliminate the CDC’s HIV Prevention Division Experts warn this could lead to higher HIV rates The ...

United States funding cuts to HIV/AIDS programmes in many African countries could lead to hundreds of thousands of deaths on the continent, health experts and aid organisations have warned.

NBC News' Jay Valle reports from a nonprofit clinic in Florida that provides free HIV care to Latinos most vulnerable to the disease. IE 11 is not supported. For an optimal experience visit our ...

The sweeping cuts in foreign aid announced Wednesday will slash HIV treatment, prevention and research, health services to treat malaria, and care for new mothers and their babies, among other ...

A ground-breaking HIV cure trial conducted in Durban has shown promising results in achieving antiretroviral therapy (ART)-free virus control. The trial revealed that 20% of participants remained ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, announced new data from two ...

UNAIDS, which provides lifesaving HIV treatment around the world, said Friday that it received a letter from Washington on Thursday terminating its agreement with UNAIDS “with immediate effect.” ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.